ClinConnect ClinConnect Logo
Search / Trial NCT00131014

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

Launched by DANA-FARBER CANCER INSTITUTE · Aug 16, 2005

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

Non Hodgkin's Lymphoma Hodgkin's Disease Chronic Lymphocytic Leukemia Lymphoproliferative Disorder Genetics

ClinConnect Summary

This clinical trial is looking into the genetic factors that may increase the risk of developing certain types of blood cancers, such as non-Hodgkin's lymphoma, Hodgkin's disease, and chronic lymphocytic leukemia (CLL). Researchers want to understand if people in families with multiple cases of these cancers have different genetic traits compared to those who develop them without a family history. The study aims to create a tumor bank, which is a collection of tissue samples and medical data that can help identify specific genes linked to these diseases.

To participate in this study, individuals must be at least 18 years old and have been diagnosed with one of the cancers mentioned, along with having a close family member (like a parent, sibling, or child) who also has a lymphoproliferative disorder. Family members, whether they have cancer or not, can also join if they agree to participate. Even if a family member has passed away, their medical records may still be included with consent from their next of kin. Participants can expect to provide samples and information that will contribute to important research aimed at understanding these cancers better.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Any individual diagnosed with non-Hodgkin's lymphoma or Hodgkin's disease or chronic lymphocytic leukemia (CLL), who has a 1st degree relative (parent, sibling or child) with a lymphoproliferative disorder; or families in which the individual has a lymphoproliferative disorder, and an unusual clustering of frequent or premature solid tumors is also observed.
  • Family members of the individual, either affected or unaffected with lymphoma, who are contacted by the individual and agree to participate in the study.
  • Deceased family members may be included in the study. Public records such as death certificates may be used to confirm the history. Consent for medical records or tissue blocks will be obtained from the deceased family member's next of kin. The hierarchy of relatives defined as next of kin is spouse, offspring, parents and siblings. Archived tissue samples may be used for genetic research.
  • Age \> 18 years
  • Exclusion Criteria:
  • Subjects without a family history of lymphoma

About Dana Farber Cancer Institute

The Dana-Farber Cancer Institute is a premier cancer research and treatment institution located in Boston, Massachusetts. Renowned for its commitment to advancing cancer care through innovative research, the institute integrates cutting-edge clinical trials with a multidisciplinary approach to patient care. With a focus on translating scientific discoveries into effective therapies, Dana-Farber collaborates with a network of leading researchers and healthcare professionals to improve outcomes for patients with cancer. The institute’s dedication to education, advocacy, and community engagement further underscores its mission to eradicate cancer and enhance the quality of life for those affected by the disease.

Locations

Boston, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Jennifer R. Brown, MD, PhD

Principal Investigator

Dana-Farber Cancer Institute

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials